Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

66.50 +0.08 (+0.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 18, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,386,639
Open 66.76
Bid (Size) 66.50 (3)
Ask (Size) 66.79 (1)
Prev. Close 66.42
Today's Range 66.13 - 66.86
52wk Range 53.63 - 71.70
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga

Performance

YTD
+14.05%
+14.05%
1 Month
+0.20%
+0.20%
3 Month
+5.02%
+5.02%
6 Month
+9.83%
+9.83%
1 Year
+12.05%
+12.05%

More News

Read More
3 Top Stocks to Invest In Right Now
Via InvestorPlace
Benzinga Before The Bell: Elon Musk May Get Info It Wants From Twitter, Apple To Lay Off 100 Recruiter Contractors, Saudi's Investment Fund Picks Stocks Of US Big Tech And Other Top Financial Stories Tuesday, August 16
Via Benzinga
UK Government Will Not Buy More AstraZeneca's COVID-19 Treatment
Via Benzinga
LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
From AstraZeneca
Via Business Wire
AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use
Via Benzinga
Benzinga Before The Bell: YouTube Plans Streaming Marketplace, Drug Pricing Bill Passes Congress, Bitcoin Could Surge To All-Time High Soon And Other Top Financial Stories Monday, August 15
Via Benzinga
Landmark Drug Pricing Reform Bill Passes Congress House
Via Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
Via Benzinga
Recap Of Friday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Blue Water Vaccines: Early Stage Developer Of Infectious Disease Vaccines
Via Talk Markets
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
Via Benzinga
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
From AstraZeneca
Via Business Wire
NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) Pioneering Innovative Hypertension Treatments
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
This Analyst Says Zentalis' Increased Focus On WEE1 Program Is 'Prudent', Slashes Price Target By 37%
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Via Benzinga
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
Via Benzinga
Recap of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Lyme Disease And Climate Change Reinvigorates Valneva's Vaccine Efforts After COVID Shot Disappointment
Via Benzinga
The Power of Science to Stop a Killer
Via Investor Brand Network
Smaller Biotechs May Pave Way For New Generation Of Therapeutics For Hard-to-Treat Neurological Disorders
Via Benzinga
The Power of Science to Stop a Killer
Via FinancialNewsMedia
AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting
Via Benzinga
TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
From AstraZeneca
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.